Med Diversified To Add State-of-the-Art Bio-Agent Detection
Monday November 5, 9:38 am Eastern Time
Press Release
SOURCE: Med Diversified
Med Diversified To Add State-of-the-Art Bio-Agent Detection Modality To Telemedicine Product Line
ANDOVER, Mass.--(BUSINESS WIRE)--Nov. 5, 2001--Med Diversified's (AMEX: MED - news) Trestle Corporation subsidiary has just completed the design of a unique bio-agent detection system, an extension of its Internet telemedicine product line, which is expected to materially reduce the time required to evaluate the presence of bio-agents like anthrax or smallpox.
Swift evaluation is critical in these difficult times due to both the potential for bio-terrorist attacks and the unfortunate reality of their recent proliferation.
Using the Internet, the product line - based in large part on the Company's much heralded Integrated MedMicroscopy and MedReach systems - allows for the evaluation of microscopic slides from remote locations, as well as the ability to access knowledge bases across the world in order to share patient data securely and collaborate in real time.
After a review and demonstration of the MedMicroscopy platform in use at facilities across the United States, Rear Admiral Todd Fisher MSC, (USN Retired), former Deputy Surgeon General, U.S. Navy, commented, ``While the MedMicroscopy system provides dramatic implications for the efficient diagnosis and treatment of disease, more significant and timely uses now exist in light of recent world events. Using the system to identify and diagnose other potential bio-terror agents may be one of its most important benefits in the short term.''
The Company believes it will benefit from the current need to speed the diagnostic and investigatory process and seek higher levels of protection from potential biological agents and will be able to effectively compete with companies such as Cepheid (Nasdaq:CPHD - news) and Bruker Daltonics (Nasdaq: BDAL - news).
Frank Magliochetti, the Company's chairman and chief executive officer, commented, ``It is unfortunate that we are now compelled to focus on these issues, but the bottom line is that the time it takes to move blood samples and environmental material to appropriate locations and then to communicate microscopic and other clinical information required for scientific evaluation is time where lives can be lost. Even a delay of one day could cost countless lives. By providing full connectivity, communication and technological uniformity throughout various agencies, potential delays could be minimized if not all together eliminated.''
Magliochetti concluded, ``We are proud to have adjusted the Trestle product lines so quickly in order to respond to this national crisis. In such a crisis, the old health care adage ''quality of care`` takes on a new meaning that Med Diversified takes seriously.''
Additional information regarding these topics can be found on the following Web sites:
potomacinstitute.org
potomacinstitute.org
hhmi.org
cdc.gov
About Med Diversified
Med Diversified is leading a worldwide transition in the medical industry. Through the efficient use of its technologies and strong management team, Med Diversified operates a series of companies in various sub-industries within health care including pharmacy, home infusion, multi-media, management, clinical respiratory services, home medical equipment, home health services and other functions. For more information, see e-medsoft.com.
Statements in this news release that relate to management's expectations, intentions or beliefs concerning future plans, expectations, events and performance are ``forward looking'' within the meaning of the federal securities laws. These forward-looking statements include assumptions, beliefs and opinions relating to the Company's business and growth strategy based upon management's interpretation and analysis of its own contractual and legal rights, management's ability to satisfy industry and consumer needs with its technologies, health-care industry trends, and management's ability to successfully develop, implement, market and/or sell its network transaction processing services, software programs, clinical and financial transaction services, and e-commerce systems to its clientele. The forward-looking statements have been made based upon representations made regarding the acquisitions involving the Company, available due diligence and analysis of those acquisitions that has been and will be performed by the Company over the past six months, and the resulting analysis of the Company's prospects. Actual results could differ materially from that indicated in our due diligence. Management's forward-looking statements further assume that the Company will be able to successfully develop and execute on its strategic relationships. Many known and unknown risks, uncertainties and other factors, including general economic conditions and risk factors detailed from time to time in news releases and the Company's filings with the Securities and Exchange Commission, may cause these forward-looking statements to be incorrect in whole or in part. The investor should review such public filings to get a comprehensive picture and analysis of all conditions and circumstances. The Company expressly disclaims any intent or obligation to update any forward-looking statements. Actual results or events could differ materially from those anticipated in the forward-looking statements due to a variety of factors set out above, including, without limitation, integration of business and management associated with the Company's business relationships and acquisitions, acceptance by customers of the Company's products, changing technology, competition in the health-care market, government regulation of health care, the Company's limited operating history, various problems that can arise in the context of a merger of companies in this manner, general economic conditions, availability of capital and other factors.
Contact:
Med Diversified
Angeline Cook
904-543-1066
acook@e-medsoft.com |
